Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 15/05/2024 BST			5-day change	1st Jan Change
0.776 ^USD	-0.22%		-1.76%	-84.18%

05-09	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-15	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

March 09, 2023 at 11:19 am

Quoin Pharmaceuticals, Ltd. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 2 million compared to USD 11.82 million a year ago.
For the full year, net loss was USD 9.38 million compared to USD 21.46 million a year ago.

Latest news about Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	03-15	MT
Quoin Pharmaceuticals Seeks M&A Opportunities	03-14	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Mar 14, 2024	03-14
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-13	CI
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	03-06	DJ
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	03-05	DJ
Top Midday Decliners	03-05	MT
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall	03-05	MT
Top Premarket Decliners	03-05	MT
Top Midday Gainers	03-04	MT
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	03-04	DJ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	03-04	CI
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	02-08	CI
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP	01-24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	12-18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome	24/10/23	CI
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA	13/09/23	CI
Quoin Pharmaceuticals Limited Seeks M&A	03/08/23	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q2 2023 Earnings Call, Aug 03, 2023	03/08/23
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/08/23	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q1 2023 Earnings Call, May 09, 2023	09/05/23
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI

Chart Quoin Pharmaceuticals, Ltd.

Duration

Period

More charts

Company Profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.776 USD

Average target price

5.8 USD

Spread / Average Target

+647.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUOIN PHARMACEUTICALS, LTD.	-84.18%	3.1M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research